Human parovirus infection in early rheumatoid and inflammatory arthritis

B J COHEN,1 M M BUCKLEY,1 J P CLEWLEY,1 V E JONES,2 A H PUTTIK,2 AND R K JACOBY2

From the 1PHLS Virus Reference Laboratory, Central Public Health Laboratory, Colindale Avenue, London; and the 2Postgraduate Medical School, University of Exeter, Royal Devon and Exeter Hospital (Wonford), Exeter

SUMMARY Evidence of recent infection with human parovirus B19 (HPV) was found in two patients with early rheumatoid arthritis (RA) and in four patients with acute inflammatory arthritis (IA). Both of the patients with RA but only one of the four patients with IA carried RA associated haplotypes. No evidence of persistent infection with HPV was found, but evidence of past infection with HPV was significantly more common in patients with RA than in controls. The results confirm the arthritogenic potential of HPV and are consistent with the hypothesis that rheumatoid arthritis may develop in a genetically predisposed patient after an arthritogenic insult such as an HPV infection.

Key words: human parovirus B19, MHC haplotypes.

Paroviruses have recently been suggested as a cause of human joint disease. A parovirus designated RA-1 was isolated from the synovial tissue of a patient with rheumatoid arthritis and shown to be pathogenic in newborn mice,1 though its involvement in human disease has not been confirmed. A second parovirus, designated human parovirus B19 (HPV), which is antigenically distinct from RA-1, has been identified as a cause of acute arthropathy, particularly in women.2 3 The most common clinical manifestation of HPV infection, however, is erythema infectiosum (fifth disease), an exanthematic infection of childhood.4 This is a mild illness without constitutional upset in children, but in adults it is frequently complicated by arthralgia, and joint swelling has been observed in up to 60% of adult cases.5 It is now apparent that HPV infection in adults may present with joint symptoms in the absence of the rash which characterises the infection in children.2 3

Arthropathy associated with HPV infection usually takes the form of a peripheral, symmetrical polyarthritis of sudden onset. It is relatively benign and most cases resolve within a few weeks.2 5 This has been confirmed by studying the effect of HPV on human volunteers.6 A few HPV infected patients have more persistent joint involvement lasting months or even years, and their signs and symptoms would fulfil the diagnostic criteria for definite rheumatoid arthritis (RA).7 In addition, a protracted case of HPV arthropathy has been described where there was an associated rise of rheumatoid factor to high titre.8 These findings raise the possibility that HPV might be an aetiological trigger in some cases of rheumatoid arthritis.

On the other hand, evidence seeming to exclude a role for HPV in rheumatoid arthritis has been obtained from a serological study in which antibody to HPV was detected in rheumatoid arthritis patients at a frequency that was not significantly different from that in healthy adults.9 Antibody in this study, however, was detected by the relatively insensitive method of counterimmunoelectrophoresis, and a further study of rheumatoid arthritis and HPV infection would seem to be warranted making use of more sensitive assays, including radioimmunoassays for HPV specific IgM and IgG and HPV antigen10 and 'dot blot' hybridisation for HPV DNA.11

In a preliminary investigation with these newer
Table 1  Clinical data on six patients following HPV infections

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Symptoms at onset</th>
<th>Skin rash</th>
<th>Joint involvement</th>
<th>Clinical course</th>
<th>RF latex</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>41</td>
<td>M</td>
<td>Painful ankles, otherwise felt well</td>
<td>None</td>
<td>MCP* joints, wrists, knees, ankles, MTP joints</td>
<td>First seen at five months after onset. Signs of definite RA. Multiple erosions at five year follow up</td>
<td>Negative at first test. Positive at five months</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>F</td>
<td>Headache and vomiting, ill for five weeks, Arthritis in feet MTP* joints during this period</td>
<td>None</td>
<td>MTP joints then remission for three months, MTP joints, wrists, elbows, ankles, knees</td>
<td>The arthritis persisted and, at presentation in the clinic, seven months after onset she had classical RA, with erosions in hands</td>
<td>Positive at three months</td>
</tr>
<tr>
<td>3</td>
<td>52</td>
<td>F</td>
<td>Headaches, felt ill, pain and swelling in hands for four days. Symptoms returned seven days later. Resolved in two weeks</td>
<td>None</td>
<td>MCP, PIP,* and MTP joints inflamed on both occasions</td>
<td>No signs or symptoms in joints one month after illness</td>
<td>Positive at two and six weeks. Negative at five months</td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>F</td>
<td>Painful hands and knees. Felt ill for a week</td>
<td>Erythema over feet</td>
<td>Wrist, MCP joints, knees</td>
<td>Five month history of arthritis, which resolved</td>
<td>Negative</td>
</tr>
<tr>
<td>5</td>
<td>40</td>
<td>F</td>
<td>Widespread joint pains and felt ill for a week</td>
<td>None</td>
<td>MCP and PIP joints, wrists, elbows, knees, ankles, neck</td>
<td>Acute morning stiffness lasted three weeks. The signs and symptoms resolved in three months</td>
<td>Positive at first test. Negative at six weeks</td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>M</td>
<td>Five days influenza-like illness, diarrhoea and stiffness in muscles</td>
<td>None</td>
<td>Shoulders, wrists, heels</td>
<td>The condition lasted eight months and resolved. Now gets occasional ankle inflammation five years after onset</td>
<td>Negative at three weeks</td>
</tr>
</tbody>
</table>

* MTP = metatarsophalangeal; MCP = metacarpophalangeal; PIP = proximal interphalangeal.
Rheumatoid factor (RF) to human IgG was measured by latex agglutination with RapiTex (Behringwerke AG, Marburg, FDR).

**Results**

Most of the 76 arthritic patients had similar symptoms initially whether or not they developed RA subsequently, and the polyarthritis associated with HPV could not be distinguished from that described by other patients in this study. First symptoms included nerve entrapment, morning stiffness, and painful joints with or without swelling. Any of the peripheral joints could be involved. A summary of clinical presentation by the six patients with evidence of HPV infection is given in Table 1.

IgM specific for parvovirus, indicating recent HPV infection, was found in two patients with early rheumatoid arthritis and in four patients with inflammatory arthritis. It was not found in any of the controls. The evolution of the anti-HPV IgM responses in the six patients is illustrated in Fig. 1, which also shows the anti-HPV IgG responses and RF titres. The presence of high levels of anti-HPV IgG which gradually fell supports the diagnosis of recent HPV infection. The highest levels of anti-HPV IgM were found in the patients with inflammatory arthritis, but these were first tested early: one, two, three, and six weeks after onset of symptoms. The levels of anti-HPV IgM were much lower in the patients with early rheumatoid arthritis, but they were first tested 12 and 20 weeks after onset. None of the patients had serological evidence of recent infection with the other viruses tested for.

Confirmation that detection of anti-HPV IgM was not a false positive reaction caused by rheumatoid factors was obtained in two ways. Firstly, sera from two patients (1 and 3, Table 1) with anti-HPV IgM and RF were absorbed with insoluble pooled human IgG coupled to Sepharose by cyanogen bromide. RF activity was bound to IgG and was subsequently eluted with 1 M ammonia, whereas anti-HPV IgM activity did not bind and was recovered in the borate-saline eluate (Table 2). Secondly, the first serum sample from 21 RA patients contained RF (Table 3), but only two were anti-HPV IgM positive and their RF titres were 1/30 and >1/200.

The prevalence of anti-HPV IgG which, in the absence of anti-HPV IgM, indicates past HPV infection was significantly higher in the patients with RA than in those with IA (p<0.01) and in the controls (p<0.01) (Table 3). The prevalence of anti-HPV IgG in the patients with IA was slightly higher than that in the controls, but the difference was not significant (p>0.5). The mean age of the RA patients, however, was greater than that of...
Human parovirus infection

Fig. 1 Anti-HPV IgM, anti-HPV IgG and rheumatoid factor in two patients with rheumatoid arthritis and four patients with inflammatory arthritis.

Table 2 Absorption of anti-HPV IgM positive sera to remove RF activity

<table>
<thead>
<tr>
<th>Patient 1 (RA)</th>
<th>Patient 3 (IA)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-HPV IgM</strong> (RIA units)</td>
<td><strong>RF</strong> (titre)</td>
</tr>
<tr>
<td>Original serum</td>
<td>5.2</td>
</tr>
<tr>
<td>Eluates from IgG:</td>
<td></td>
</tr>
<tr>
<td>borate-saline:</td>
<td>3.0</td>
</tr>
<tr>
<td>1 M NH₃:</td>
<td>NT*</td>
</tr>
<tr>
<td>Eluates from BSA*:</td>
<td></td>
</tr>
<tr>
<td>borate-saline:</td>
<td>3.1</td>
</tr>
<tr>
<td>1 M NH₃:</td>
<td>NT</td>
</tr>
</tbody>
</table>

*NT=not tested; BSA=bovine serum albumin.

Sera (0.25 ml volumes) were applied to columns (4×0.7 cm) of pooled human IgG-Sepharose and BSA-Sepharose and were eluted with borate-saline pH 8.0 followed by 1 M NH₃. Ammonia eluates were neutralised with 1 M propionic acid before testing for RF activity but were too dilute to test for anti-HPV IgM activity.
the controls, which in turn was greater than that of the patients with IA; but even when allowance for age was made anti-HPV IgG was significantly commoner in patients with RA than in controls. For example, in those more than 40 years old anti-HPV IgG was present in 30 of 31 RA patients and in 27 of 42 controls (p<0.01).

Neither HPV antigen nor DNA was found in any of the synovial fluids tested. Anti-HPV IgG was found in synovial fluids at levels that generally reflected the level of anti-HPV IgG in the corresponding serum (results not shown).

HLA haplotypes of the six patients with evidence of recent HPV infection are presented in Table 4. Both of the two patients with RA carried a haplotype associated with RA, namely Bw62 BfS C4A*3 C4B*3 DR4 and A2 B7 DR4. Of the four patients with IA, three had haplotypes which are not associated with RA, but the fourth (patient 3) carried the same RA associated haplotype as RA patient No 1, Bw62 BfS C4A*3 C4B*3 DR4. Moreover, the mother of patient No 3 also carried this haplotype and has severe classical RA.

A common haplotype, B7 BfS C4A*3 C4B*1 DR2, which is negatively associated with RA and may therefore act as protective haplotype against the disease, was carried by both RA patient 2 and by IA patient 4.

**Discussion**

Definite serological evidence of recent HPV infection was found in three patients with inflammatory arthritis (patients 3, 4, and 5, Table 1 and Fig. 1). Anti-HPV IgM was present in high levels in acute phase sera and fell to low levels or was absent in convalescent sera. Anti-HPV IgG levels in these three patients initially rose and then declined but were still present eight months or more after onset of symptoms. One other patient with inflammatory arthritis (patient 6, Table 1 and Fig. 1) had only trace amounts of anti-HPV IgM in the acute phase, but the pattern of falling levels of anti-HPV IgG in follow up sera was suggestive of recent infection. The clinical picture in these four patients was consistent with that described previously in HPV arthropathy.

Less definite evidence of recent HPV infection was found in two patients with rheumatoid arthritis (1 and 2, Table 1 and Fig. 1). They had only low levels of anti-HPV IgM in the earliest available serum, but this disappeared from subsequent specimens which, together with coincident changes in anti-HPV IgG levels, indicated recent HPV infection. Sera from these patients, however, contained high levels of rheumatoid factor and this is known to give rise to non-specific results when measuring virus specific IgM, though such reactions are thought to be minimised with the ‘antibody capture’ type assays used in this study. Since follow up sera from the same patients and other sera with high titres of RF were negative for anti-HPV IgM and since absorption with insoluble IgG removed RF but not anti-HPV IgM activity from the sera of two patients it is considered that the results obtained with these early rheumatoid sera represent true positive reactions for anti-HPV IgM. The low level of anti-HPV IgM more probably reflects the timing of the specimens, which were collected three and five months after the onset of symptoms. For
specimen collected of optimal months have been coincidental and 1985 larger clusters year another in the clinic patients among 1985 HPV large are such as an greater and infection at more likely lymphocytic choriomeningitis virus, polyoma virus, and retrovirus—induce or accelerate SLE-like disease and autoimmunity in genetically susceptible strains of mice. Both of our RA patients carry major histocompatibility complex (MHC) haplotypes associated with a risk of developing RA. In contrast, three of the four HPV infected IA patients have no RA associated haplotypes. One of these patients carries B44 DR4, which has been associated with RA in another study, but her extended haplotype, when her compotype is included, is not RA associated. The other patient carries a haplotype A3 B7 BfS C4A*3 C4B*1 DR2 considered to be protective against RA. The exception is IA patient 3, who carries the haplotype strongly associated with RA in this region Bw62 BfS C4A*3 C4B*3 DR4. Moreover, she showed a transient rise in RF during the infection, and her mother, who also carries the same haplotype, has severe classical RA. Her infection, however, occurred only recently, in July 1985, and it may be too soon for a reliable clinical prognosis. From our other studies this RA associated haplotype is more likely to be associated with autoimmunity expressed by rheumatoid factor together with the clinical features of RA than with susceptibility to the arthritogenic effects of an HPV infection. Tissue typing of more HPV infected patients is necessary to investigate this point.

The prevalence of anti-HPV IgG in patients with rheumatoid arthritis in this study (92.3%) was significantly higher than that in controls (60-9%). In a previous study by Lefrere and colleagues the prevalence of anti-HPV in rheumatoid arthritis patients (33-3%) was also higher than in controls (25-3%), but the difference was not considered significant. The difference in the prevalence of anti-HPV in their study and in ours can be explained in terms of the sensitivity of the assays used to measure the antibody. They used counterimmunoelctrophoresis, in which anti-HPV becomes undetectable 12 to 24 months after infection, whereas we used a more sensitive radioimmunoassay. It appears, therefore, that our series of rheumatoid arthritis patients contained an excess of subjects with a past exposure to HPV.

On the other hand, the higher prevalence of anti-HPV IgG in our rheumatoid arthritis patients could be due to the higher mean age of this group (54-8 years) compared with that of the controls (45-2 years). Although acquisition of antibody to HPV occurs principally in childhood between the ages of 6 and 10 years, there is a second, smaller peak of HPV infection between 30 and 40 years, and it seems likely that a continued gradual increase in the prevalence of anti-HPV IgG occurs with age. It is unlikely, however, that age accounts for the difference between our rheumatoid arthritis patients and controls because when only older subjects are considered (e.g., > 40 years) the prevalence of anti-HPV IgG is still significantly higher in patients with rheumatoid arthritis than in controls.

The increased prevalence of anti-HPV IgG in our RA patients is reminiscent of the reported high titres of antibodies to Epstein-Barr virus (EBV) related antigens in RA. The increase in antibodies to EBV has been attributed to a defect in regulatory T lymphocytes, which are specific for EBV, and not to an overall defect in immunoregulatory T cell function. A defect in HPV specific T lymphocytes might occur in RA patients and this warrants investigation. In contrast with the persistence of EBV infected cells in most RA patients and normal individuals there were no signs of persistent HPV infection in our RA or IA patients. No virus was detected in synovial fluids and the anti-HPV IgM response did not persist. These findings suggest that while HPV infection may be a triggering factor in rheumatoid arthritis in a genetically predisposed individual the virus is unlikely to have a continuing role in the pathogenesis of the disease. Moreover, the low incidence of HPV infection in our patients and, in a related study, the appearance of RF at widely different times after onset of arthritic symptoms implies that there must be other agents involved in initiating the disease.
Addendum

Recently we have tested an additional 74 patients (30 with RA and 44 with IA) for evidence of HPV infection at the onset of their arthritis. Two of the patients with RA and one with IA had detectable anti-HPV IgM and high levels of anti-HPV IgG within months of onset. These levels had fallen in follow up samples. Results for anti-HPV IgM in the two patients with RA were not false positives due to RF: this possibility was excluded by first removing RF with solid phase IgG. Therefore, from a total of 69 patients with RA we now have evidence that four suffered a parovirus infection at the onset of their rheumatoid arthritis.

This work was supported at the PHLS Virus Reference Laboratory by a grant from the Arthritis and Rheumatism Council and at the Royal Devon and Exeter Hospital by grants from the Northcott Devon Medical Foundation, the Wellcome Trust, and the Medical Research Council. We are grateful to Mrs E Williamson and Mr M Boyce for help with tissue typing.

References

Human parvovirus infection in early rheumatoid and inflammatory arthritis.

Ann Rheum Dis 1986 45: 832-838
doi: 10.1136/ard.45.10.832

Updated information and services can be found at:
http://ard.bmj.com/content/45/10/832

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/